2H-苯并吡喃-3-甲酸 | 22649-28-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡喃
• 中文名称: 2H-苯并吡喃-3-甲酸
• 中文别名: 2H-色烯-3-羧酸
• 英文名称: 2H-chromene-3-carboxylic acid
• 英文别名: chromene-3-carboxylic acid；2H-1-benzopyran-3-carboxylic acid
• CAS: 22649-28-1
• 化学式: C₁₀H₈O₃
• mdl: MFCD00202020
• 分子量: 176.172
• InChiKey: DEBZQUFVQZPPLC-UHFFFAOYSA-N

物化性质

• 熔点：
  184-186°C
• 沸点：
  327.3±41.0 °C(Predicted)
• 密度：
  1.346±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  46.5
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  Xi
• 危险类别码：
  R36/37/38
• 海关编码：
  2916190090
• 安全说明：
  S26,S36/37/39
• 危险性防范说明：
  P261,P280,P305+P351+P338
• 危险性描述：
  H302,H312,H315,H319,H332,H335
• 储存条件：
  存储条件：2-8°C，密闭保存，置于干燥处。

SDS

Name:	2H-chromene-3-carboxylic acid 90+% Material Safety Data Sheet
Synonym:
CAS:	22649-28-1

Section 1 - Chemical Product MSDS Name:2H-chromene-3-carboxylic acid 90+% Material Safety Data Sheet
Synonym:

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
22649-28-1	2H-Chromene-3-carboxylic acid	90+%	unlisted

Hazard Symbols: XN
Risk Phrases: 20/21/22 36/37/38

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Harmful by inhalation, in contact with skin and if swallowed.
Irritating to eyes, respiratory system and skin.
Potential Health Effects
Eye:
Causes eye irritation.
Skin:
Causes skin irritation. Harmful if absorbed through the skin.
Ingestion:
Harmful if swallowed. May cause irritation of the digestive tract.
Inhalation:
Harmful if inhaled. Causes respiratory tract irritation.
Chronic:
Not available.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Get medical aid. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container.

---

Section 7 - HANDLING and STORAGE
Handling:
Avoid breathing dust, vapor, mist, or gas. Avoid contact with skin and eyes.
Storage:
Store in a cool, dry place. Store in a tightly closed container.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 22649-28-1: Personal Protective Equipment Eyes: Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: pale yellow
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 187 - 189 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C10H8O3
Molecular Weight: 176.17

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not available.
Conditions to Avoid:
Incompatible materials.
Incompatibilities with Other Materials:
Strong oxidizing agents, reducing agents, bases, amines.
Hazardous Decomposition Products:
Carbon monoxide, carbon dioxide.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 22649-28-1 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
2H-Chromene-3-carboxylic acid - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Shipping Name: TOXIC SOLID, ORGANIC, N.O.S.*
Hazard Class: 6.1
UN Number: 2811
Packing Group: III
IMO
Shipping Name: TOXIC SOLID, ORGANIC, N.O.S.
Hazard Class: 6.1
UN Number: 2811
Packing Group: III
RID/ADR
Shipping Name: TOXIC SOLID, ORGANIC, N.O.S.
Hazard Class: 6.1
UN Number: 2811
Packing group: III

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: XN
Risk Phrases:
R 20/21/22 Harmful by inhalation, in contact with
skin and if swallowed.
R 36/37/38 Irritating to eyes, respiratory system
and skin.
Safety Phrases:
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 36/37/39 Wear suitable protective clothing, gloves
and eye/face protection.
WGK (Water Danger/Protection)
CAS# 22649-28-1: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 22649-28-1 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 22649-28-1 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  2H-苯并吡喃-3-甲酸 在 叠氮磷酸二苯酯 、 三乙胺 作用下， 以 二氯甲烷 、 甲苯 为溶剂， 反应 4.17h， 生成 3-isocyanato-2H-chromene
  参考文献：
  名称：

  通过酶促还原胺化合成药学相关的 2-氨基四氢萘和 3-氨基色满衍生物

  摘要：

  药学相关的 2-氨基四氢萘和 3-氨基色满衍生物的生物催化合成是使用亚胺还原酶 (IRED) 在制备规模上实现的，对大多数产品显示出对映互补选择性，产率高达 91%。Ebalzotan、Robalzotan、Alnespirone 和 5-OH-DPAT 的前体以及帕金森病药物罗替高汀的前体均通过 3 步化学酶促方法成功合成。

  DOI：

  10.1002/anie.202110321
• 作为产物：
  描述：

  tert-butyl 2H-chromene-3-carboxylate 在 三氟乙酸 作用下， 以46%的产率得到2H-苯并吡喃-3-甲酸
  参考文献：
  名称：

  取代的色烯作为有效的口服活性5-脂氧合酶抑制剂。

  摘要：

  合成了一系列色烯衍生物，并对其体外和离体的5-脂氧合酶（5-LO）抑制活性进行了评估。这些化合物的制备方法是将适当的水杨醛与α，β-不饱和羰基化合物缩合，然后转化为相应的异羟肟酸或N-羟基脲。如豚鼠PMN 5-LO测定所表明的，将苯氧基或对氟苯氧基取代基放置在亚甲基环的6位上导致体外效能的显着提高。通常，在离体狗模型中，二氯异羟肟酸的性能较差。另一方面，用N-羟基脲代替异羟肟酸的功能在狗模型中产生了有效且持久的5-LO抑制剂。在大多数情况下，色烯N-羟基脲的口服功效与其体外活性非常相关。化合物43（CGS 23885）和55（CGS 24891）是制备的最有效的抑制剂，其IC50值分别为48和51 nM。静脉内（iv）给药1.0 mg / kg后，化合物43和55的作用持续时间（DA）值分别为21和20 h。在口服（po）实验中，以1.0 mg / kg的剂量，43和55的DA分别为14和15

  DOI：

  10.1021/jm00075a013

文献信息

• ANTAGONISTS OF THE TRPV1 RECEPTOR AND USES THEREOF
  申请人：Bayburt Erol K.

  公开号：US20080153871A1

  公开（公告）日：2008-06-26

  The present application is directed to compounds that are TRPV1 antagonists and have formula (I) wherein variables Ar 1 , L 1 , R 1 , R 2 , R 3 , R 4 , R 5 , Y 1 , Y 2 , and Y 3 , are as defined in the description, which are useful for treating disorders caused by or exacerbated by vanilloid receptor activity.

  本申请涉及的化合物是TRPV1拮抗剂，其化学式为（I），其中变量Ar1，L1，R1，R2，R3，R4，R5，Y1，Y2和Y3如描述中所定义，对于治疗由辣椒素受体活性引起或加剧的疾病是有用的。
• [EN] BENZIMIDAZOLE OR INDOLE AMIDES AS INHIBITORS OF PIN1<br/>[FR] AMIDES DE BENZIMIDAZOLE OU D'INDOLE EN TANT QU'INHIBITEURS DE PIN1
  申请人：PFIZER

  公开号：WO2006040646A1

  公开（公告）日：2006-04-20

  The invention relates to compounds of the formula (1) and to pharmaceutically acceptable salts and solvates thereof, wherein the variables are defined herein. The invention also relates to methods of treating abnormal cell growth in mammals by administering the compounds of formula (1) and to pharmaceutical compositions for treating such disorders that contain the compounds of formula (1). The invention also relates to methods of preparing the compounds of formula (1).

  这项发明涉及公式（1）的化合物，以及其药学上可接受的盐和溶剂化合物，其中变量在此处定义。该发明还涉及通过给予公式（1）的化合物来治疗哺乳动物中的异常细胞生长的方法，以及用于治疗包含公式（1）化合物的这类疾病的药物组合物。该发明还涉及制备公式（1）化合物的方法。
• Efficient Syntheses of New Heteroarotinoids through Functional Pyridylzinc Reagents and Palladium-Catalyzed Cross-Coupling Reactions
  作者：Mouâd Alami、Jean-François Peyrat、Larbi Belachmi、Jean-Daniel Brion

  DOI：10.1002/1099-0690(200111)2001:22<4207::aid-ejoc4207>3.0.co;2-3

  日期：2001.11

  rings in association with pyridyl or ethynylpyridyl moieties, from 6-bromo-2-pyridylzinc chloride (11) is described. This new functional heteroarylzinc reagent, readily accessible from 2,6-dibromopyridine, may undergo a selective palladium-catalyzed carbon−carbon bond-forming reaction to yield the corresponding 6-substituted-2-bromopyridines 13. Further manipulation of the remaining bromine atom in 13

  描述了由 6-溴-2-吡啶基氯化锌 (11) 聚合合成带有色烯环和吡啶基或乙炔基吡啶基部分的杂芳烃类化合物 4、5a 和 5b。这种新的功能杂芳基锌试剂很容易从 2,6-二溴吡啶中获得，可以进行选择性钯催化的碳-碳键形成反应，以产生相应的 6-取代-2-溴吡啶 13。 13得到锌衍生物14，随后在钯催化条件下与4-碘苯甲酸乙酯偶联得到杂芳烃4。取代的溴吡啶13或三氟甲磺酸酯22与适当的炔烃在Sonogashira条件下偶联得到相应的杂芳烃5a、5b和6 .
• Iridium-Catalyzed Enantioselective Hydrogenation of Unsaturated Heterocyclic Acids
  作者：Song Song、Shou-Fei Zhu、Liu-Yang Pu、Qi-Lin Zhou

  DOI：10.1002/anie.201301341

  日期：2013.6.3

  binding: A highly enantioselective hydrogenation of unsaturated heterocyclic acids has been developed by using chiral iridium/spirophosphino oxazoline catalysts (see scheme; BArF−=tetrakis[3,5‐bis(trifluoromethyl)phenyl]borate, Boc=tert‐butoxycarbonyl). This reaction provided an efficient method for the preparation of optically active heterocyclic acids with excellent enantioselectivities.

  螺旋结合：一种高度对映选择性的不饱和杂环羧酸的加氢已经通过使用手性铱/ spirophosphino恶唑啉催化剂开发（参见方案; BAR ˚F - =四[3,5-双（三氟甲基）苯基]硼酸盐，的Boc =叔丁氧羰基） 。该反应提供了制备具有优异对映选择性的旋光杂环酸的有效方法。
• Aryl- and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
  申请人：Molino F. Bruce

  公开号：US20060052378A1

  公开（公告）日：2006-03-09

  The compounds of the present invention are represented by the chemical structure found in Formula (I): wherein: the carbon atom designated * is in the R or S configuration; and X is a fused bicyclic carbocycle or heterocycle selected from the group consisting of benzofuranyl, benzo[b]thiophenyl, benzoisothiazolyl, benzoisoxazolyl, indazolyl, indolyl, isoindolyl, indolizinyl, benzoimidazolyl, benzooxazolyl, benzothiazolyl, benzotriazolyl, imidazo[1,2-a]pyridinyl, pyrazolo[1,5-a]pyridinyl, [1,2,4]triazolo[4,3-a]pyridinyl, thieno[2,3-b]pyridinyl, thieno[3,2-b]pyridinyl, 1H-pyrrolo[2,3-b]pyridinyl, indenyl, indanyl, dihydrobenzocycloheptenyl, tetrahydrobenzocycloheptenyl, dihydrobenzothiophenyl, dihydrobenzofuranyl, indolinyl, naphthyl, tetrahydronaphthyl, quinolinyl, isoquinolinyl, 4H-quinolizinyl, 9aH-quinolizinyl, quinazolinyl, cinnolinyl, phthalazinyl, quinoxalinyl, benzo[1,2,3]triazinyl, benzo[1,2,4]triazinyl, 2H-chromenyl, 4H-chromenyl, and a fused bicyclic carbocycle or fused bicyclic heterocycle optionally substituted with substituents (1 to 4 in number) as defined in R 14 ; with R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , and R 14 defined herein.

  本发明的化合物由以下式中的化学结构表示（I）： 其中： 指定为*的碳原子处于R或S构型；X是从苯并呋喃基、苯并噻吩基、苯并异噻唑基、苯并异噁唑基、吲哚基、吲哚基、异吲哚基、吲哚啉基、苯并咪唑基、苯并噁唑基、苯并噻唑基、苯并三唑基、咪唑并[1,2-a]吡啶基、吡唑并[1,5-a]吡啶基、[1,2,4]三唑并[4,3-a]吡啶基、噻吩并[2,3-b]吡啶基、噻吩并[3,2-b]吡啶基、1H-吡咯并[2,3-b]吡啶基、茚基、茚基、二氢苯并环庚烯基、四氢苯并环庚烯基、二氢苯并噻吩基、二氢苯并呋喃基、吲啉基、萘基、四氢萘基、喹啉基、异喹啉基、4H-喹啉基、9aH-喹啉基、喹唑啉基、喜啉基、邻苯二嗪基、喹啉基、苯并[1,2,3]三嗪基、苯并[1,2,4]三嗪基、2H-香豆素基、4H-香豆素基或者是一个可选地用取代基（1至4个）取代的螺联苯环或螺联杂环的螺联双环碳环或螺联双环杂环； 其中R1、R2、R3、R4、R5、R6、R7、R8和R14在此处定义。